COMMUNIQUÉ DE PRESSE publié le 04/10/2024 à 07:00, il y a 1 mois 17 jours Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Relief Therapeutics reports positive results from RLF-OD032 proof-of-concept clinical study for Phenylketonuria, showing bioequivalence with KUVAN(R) in managing PKU. RLF-OD032 aims to offer a patient-friendly, portable solution for PKU treatment Clinical Study Relief Therapeutics RLF-OD032 Bioéquivalence Phenylketonuria
BRÈVE publiée le 23/09/2024 à 07:05, il y a 1 mois 28 jours Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement FDA Approval Relief Therapeutics Milestone Payment Niemann-Pick Disease SWK Funding
BRÈVE publiée le 23/09/2024 à 07:05, il y a 1 mois 28 jours Relief Therapeutics annonce un jalon de 2 millions de dollars dans le cadre d'un accord de vente de redevances Approbation De La FDA THÉRAPEUTIQUE DE SECOURS Paiement D'étape Maladie De Niemann-Pick Financement SWK
COMMUNIQUÉ DE PRESSE publié le 23/09/2024 à 07:00, il y a 1 mois 28 jours Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement Relief Therapeutics announced $2 million milestone payment under royalty sales agreement after FDA approval of arimoclomol for Niemann-Pick Disease Type C treatment FDA Approval Relief Therapeutics Milestone Payment Arimoclomol Royalty Sales Agreement
Publié le 21/11/2024 à 06:58, il y a 7 heures 5 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 5 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 5 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 55 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 43 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 13:30, il y a 33 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 33 minutes Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 1 heure 3 minutes Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 1 heure 3 minutes Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 1 heure 3 minutes Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:41, il y a 22 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 27 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 48 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
